Back to News
Market Impact: 0.4
Novo's CagriSema Outshines Zepbound in Key Phase III Weight-Loss Study
Source: zacks.com
Healthcare & BiotechCompany FundamentalsProduct Launches
Novo Nordisk's CagriSema delivered greater weight loss than Eli Lilly's tirzepatide in type 2 diabetes and achieved 21% weight loss in obesity. The results strengthen Novo Nordisk's late-stage obesity and diabetes pipeline and could improve its competitive positioning in the GLP-1 treatment market.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.58
Ticker Sentiment
LLY-0.45
More News
- Dozens of people sue GLP-1 drug companies over alleged vision loss
- Roche obesity drug shows 15.5% weight loss in diabetes trial
- South Korean solar stocks jump as curbs on Chinese sector expected to remain in place
- Trump Says US Team Met With Iranians at UNGA
- Meta is breaking out after introducing Muse AI agent. Where the stock is going, according to the charts
- Australia’s IDP shares drop after rejecting $494 mln Blackstone offer